BIOBADATOP Spanish Atopic Dermatitis Registry: Description and Early Findings

Area of Science:

• Dermatology
• Clinical Pharmacology
• Epidemiology

Background:

• Advances in understanding atopic dermatitis (AD) have transformed treatment options.
• Real-world clinical practice data is crucial for evaluating these advancements.
• The Spanish BIOBADATOP registry was established to capture such data.

Purpose of the Study:

• To describe patient characteristics, diagnoses, treatments, and adverse events (AEs) in patients with atopic dermatitis (AD) treated systemically.
• To analyze data from the prospective, multicenter BIOBADATOP registry.
• To provide initial insights into the safety and effectiveness of AD therapies in a real-world setting.

Main Methods:

• Analysis of data from the Spanish Atopic Dermatitis Registry (BIOBADATOP).
• Inclusion of patients of all ages with AD requiring systemic therapy (conventional or novel drugs).
• Collection and review of patient characteristics, diagnoses, treatments, and adverse events (AEs) during follow-up.

Main Results:

• Data from 258 patients and 347 systemic treatments were analyzed.
• Treatment discontinuation occurred in 29.4% of cases, primarily due to lack of effectiveness (10.7%).
• 132 adverse events (AEs) were reported, with 86 linked to systemic treatments, most commonly dupilumab and cyclosporine. Common AEs included conjunctivitis and headache. One severe AE (acute mastoiditis) was associated with cyclosporine.

Conclusions:

• Initial findings from the BIOBADATOP registry are limited by short follow-up periods.
• No severe adverse events (AEs) were reported for novel systemic therapies at the time of analysis.
• The BIOBADATOP registry is expected to provide valuable data on the effectiveness and safety of conventional and novel systemic therapies for atopic dermatitis (AD).